SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-157328
Filing Date
2024-06-07
Accepted
2024-06-07 16:07:29
Documents
13
Period of Report
2024-06-04
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d843373d8k.htm   iXBRL 8-K 31745
  Complete submission text file 0001193125-24-157328.txt   154204

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aldx-20240604.xsd EX-101.SCH 2849
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20240604_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20240604_pre.xml EX-101.PRE 11260
16 EXTRACTED XBRL INSTANCE DOCUMENT d843373d8k_htm.xml XML 3642
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 241029379
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)